SEQUENOM Records Strong Fourth Quarter MassARRAY(R) System Placements
SEQUENOM, Inc. (Nasdaq: SQNM) today reported nine MassARRAY system placements in the fourth quarter of 2004 for a total of twenty systems for the year. The sharp increase in system placements was primarily driven by market acceptance of the recently introduced MassARRAY Compact system.
“We are pleased with the successful execution of our strategy to enter the clinical research market,” said Mike Terry, SEQUENOM’s Executive Vice President, Sales and Marketing. “In the fourth quarter, we noted new customers in a variety of leading clinical research institutions in North America, Europe and Asia. The increase in international sales demonstrates the success of our global marketing efforts. With offices in Europe, North America and Asia Pacific, we are well positioned to respond to the needs of the clinical genetics community worldwide.”
SEQUENOM intends to leverage MassARRAY technology as a significant contributor in the development of molecular medicine, which encompasses applications in pharmacogenomics, pharmacogenetics, disease predisposition testing, disease prognosis, early cancer detection and non-invasive prenatal testing. These fields share the need for analytical applications that define disease on a molecular level and require the high degree of quality and reliability that MassARRAY products provide.
SEQUENOM has expanded beyond the discovery and academic research market to include the clinical analysis market. This combined applied genetic analysis market is significantly larger and represents an area of future sales growth and opportunity for the Company. Originally developed as a genotyping platform, the continually expanding application portfolio for the MassARRAY technology now includes microbial typing, mutation detection, gene expression profiling, genetic trace analysis, and epigenetic analysis.
About SEQUENOM
SEQUENOM is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, molecular medicine and agricultural applications. The Company’s proprietary MassARRAY system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts.
SEQUENOM(R) and MassARRAY(R) are registered trademarks of SEQUENOM, Inc.
